AI startup Lila Sciences is closing in on a Series A funding round exceeding $300 million to advance its autonomous scientific research platform. The company aims to develop 'scientific superintelligence' by integrating AI technologies into data analysis, experimental design, and hypothesis generation. This substantial capital raise reflects a growing trend of applying artificial intelligence to accelerate breakthroughs in biotechnology and drug discovery.